Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial
Authors
Kristeleit, R.Clamp, Andrew R
Gourley, C.
Roux, R.
Hall, M.
Devlin, M. J.
Nirsimloo, R.
Kounnis, V.
Hughes, L.
Counsell, N.
Farrelly, L.
Miller, R.
Affiliation
Department Of Oncology, Guy's and St Thomas' NHS Foundation Trust, SE1 9RTIssue Date
2022
Metadata
Show full item recordCitation
Kristeleit R, Clamp AR, Gourley C, Roux R, Hall M, Devlin MJ, et al. Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial. Annals of Oncology. 2022 Sep;33(7):S783-S. PubMed PMID: WOS:000866211600514.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1054Additional Links
https://dx.doi.org/10.1016/annonc/annonc1054Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1054